The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

The US agency maintains that Glatiramer acetate is an approved medicine to treat patients with relapsing forms of MS. (Image Credits: Reuters) The U.S. Food and Drug Administration (FDA ...

The FDA added a boxed warning about rare cases of anaphylaxis associated with the multiple sclerosis (MS) drug glatiramer ...

The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...

The following is a summary of “Cost–consequence analysis of early vs. delayed natalizumab use in highly active ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.